Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
NCT06608004 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-05-15
Summary
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive diffuse muscular paralysis due to the inexorable loss of motor neurons in the primary motor cortex, the corticospinal tract, the brain stem and the spinal cord.
Over the course of the disease, when the phrenic motor neurons are involved, diaphragmatic weakness develops, leading to restrictive respiratory failure, which is the main cause of morbidity and mortality. Non-invasive ventilation (NIV) compensates for diaphragm failure and corrects the associated symptoms, and has been shown to prolong patient survival and improve quality of life.
Undernutrition is another recognised prognostic factor. Several mechanisms have been described, foremost of which are a state of hypermetabolism and a reduction in food intake secondary to chewing difficulties, dysphagia, a loss of dexterity in the upper limbs, a disturbance in salivary secretion or psychological disorders. In addition, diaphragmatic dysfunction plays a direct role in the onset of undernutrition, as compensatory contraction of the accessory neck muscles increases resting energy expenditure.
However, the hedonic sensations triggered by a meal play a role in controlling food intake beyond the simple energy balance between calorie intake and energy expenditure. Olfacto-gustatory sensoriality could therefore play a role in the nutritional status of patients suffering from ALS.
Diaphragmatic dysfunction may also influence nutritional status by other mechanisms. For example, the reduction in inspiratory capacity associated with diaphragmatic insufficiency reduces olfaction in a group of tetraplegic patients. Central sensory impairment could exacerbate this phenomenon. Although it is conventionally considered that there are no sensory manifestations during the course of ALS, minor but diffuse abnormalities of the nerves and sensory action potentials have been observed. A central alteration in olfacto-gustatory sensoriality could be part of the neurological manifestations of ALS. In addition, olfactory deficits occur in other neuromuscular diseases with central involvement, such as myasthenia, Parkinson\'s or Alzheimer\'s disease, in the absence of concomitant cognitive or diaphragmatic impairment.
Our hypothesis is that impaired olfacto-gustatory function favours the onset of undernutrition in ALS.
Current nutritional management consists of ensuring adequate calorie intake by prescribing oral food supplements or inserting a gastrostomy. Taking personalised account of food preferences during dietary advice or of a potential olfacto-gustatory deficit, by reinforcing smells or tastes during food consumption, would be an interesting additional therapeutic avenue for improving patients\' nutritional status, quality of life and prognosis
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
- OTHER
-
test taking
Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\' Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
Sponsors & Collaborators
-
Centre Hospitalier Universitaire Dijon
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-12
- Primary Completion
- 2029-05-12
- Completion
- 2029-05-12
Countries
- France
Study Locations
More Related Trials
-
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
NCT06147843 ·Status: RECRUITING ·Phase: NA
-
Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype
NCT01823380 ·Status: COMPLETED ·Phase: NA
-
Contralateral R1 in Amyotrophic Lateral Sclerosis
NCT06206629 ·Status: COMPLETED
-
A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis
NCT00213824 ·Status: TERMINATED
-
Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01504009 ·Status: COMPLETED ·Phase: NA
-
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
NCT02424669 ·Status: UNKNOWN ·Phase: NA
-
Study of the Effects Strengthening Exercises in Individuals With ALS
NCT00204464 ·Status: COMPLETED ·Phase: PHASE2
-
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)
NCT05107349 ·Status: RECRUITING ·Phase: NA
-
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079 ·Status: RECRUITING ·Phase: NA
-
Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS
NCT05747937 ·Status: RECRUITING ·Phase: NA
-
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03580616 ·Status: TERMINATED ·Phase: PHASE2
-
Perception of Unpleasant Sensations During Study Procedures in ALS Patients
NCT06325865 ·Status: COMPLETED
-
Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association With Clinical Phenotypes
NCT06771414 ·Status: NOT_YET_RECRUITING
-
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
NCT01091142 ·Status: COMPLETED ·Phase: PHASE1
-
potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis
NCT06441448 ·Status: RECRUITING
-
Determining the Safety of L-serine in ALS
NCT01835782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
NCT02794857 ·Status: COMPLETED ·Phase: PHASE2
-
EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)
NCT00718458 ·Status: COMPLETED
-
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
NCT02969759 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Digital Assessment of Speech and Fine Motor Control in ALS
NCT06315673 ·Status: RECRUITING
-
Neuromuscular Magnetic Stimulation in ALS Patients
NCT03618966 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Performance of a Diagnostic Test in ALS
NCT02759913 ·Status: UNKNOWN
-
Spinal Interneuron Excitability in ALS
NCT02429492 ·Status: COMPLETED ·Phase: NA
-
Exposure to Neurotoxins as Risk Factors for ALS
NCT00340301 ·Status: COMPLETED